Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

27.28 -0.21 (-0.76%)
Streaming Delayed Price Updated: 2:43 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 776,591
Open 27.00
Bid (Size) 27.25 (1)
Ask (Size) 27.32 (7)
Prev. Close 27.49
Today's Range 26.62 - 27.74
52wk Range 24.34 - 73.80
Shares Outstanding 116,457,008
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
Via Benzinga
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
Via Benzinga

Performance

YTD
-55.48%
-55.48%
1 Month
+1.49%
+1.49%
3 Month
-31.55%
-31.55%
6 Month
-37.43%
-37.43%
1 Year
-44.73%
-44.73%

More News

Read More
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
Via Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
Via Benzinga
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
Via Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Via The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
Via Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Via The Motley Fool
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
Via Benzinga
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
Via Benzinga
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
Via Investor's Business Daily
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.